Evidence map›Paper›PMID 39570650›Full record

ArticleMolecular cancer therapeutics2025

Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling.

Fanny Volat, Ragini Medhi, Lauren Z Maggs, Marcel A Deken, Alice Price, Lauren Andrews, Jonathan Clark, Diane Taylor, Alan Carruthers, Ewan Taylor-Smith and 12 more

Abstract read
In one paragraph

Article in Molecular cancer therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Advances in Lipid Metabolism Reprogramming in Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2026
    Review
  3. Article
  4. Article
  5. Cytokines and cancer-associated fibroblasts.Journal of hematology & oncology · 2026
    Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Fanny Volat *Cancer Research Horizons, Cambridge, United Kingdom.ORCID 0000-0001-5463-6002
Ragini Medhi *Cancer Research Horizons, Cambridge, United Kingdom.ORCID 0000-0002-2780-0708
Lauren Z Maggs *Cancer Research Horizons, Cambridge, United Kingdom.ORCID 0000-0002-8053-2749
Marcel A DekeniOnctura BV, Amsterdam, the Netherlands.ORCID 0009-0005-7324-7631
Alice PriceCancer Research Horizons, Cambridge, United Kingdom.ORCID 0009-0002-9509-6326
Lauren AndrewsCancer Research Horizons, Cambridge, United Kingdom.ORCID 0009-0005-9548-8604
Jonathan ClarkThe Babraham Institute, Cambridge, United Kingdom.ORCID 0000-0003-4095-8013
Diane TaylorThe Babraham Institute, Cambridge, United Kingdom.ORCID 0009-0002-4940-9352
Alan CarruthersCancer Research Horizons, Cambridge, United Kingdom.ORCID 0009-0008-2701-672X
Ewan Taylor-SmithCancer Research Horizons, Cambridge, United Kingdom.ORCID 0009-0008-6311-4298
Natalia PachecoCancer Research Horizons, Cambridge, United Kingdom.ORCID 0000-0003-1359-4955
Simon A RudgeThe Babraham Institute, Cambridge, United Kingdom.ORCID 0000-0003-2172-9709
Amy FraserCancer Research Horizons, Cambridge, United Kingdom.ORCID 0009-0007-4883-7538
Andrea F Lopez-ClavijoThe Babraham Institute, Cambridge, United Kingdom.ORCID 0000-0002-6249-7767
Bebiana C SousaThe Babraham Institute, Cambridge, United Kingdom.ORCID 0000-0002-1356-6789
Zoë JohnsoniOnctura SA, Geneva, Switzerland.ORCID 0000-0002-4120-2579
Giusy Di ConzaiOnctura SA, Geneva, Switzerland.ORCID 0000-0003-1353-5867
Lars van der VeeniOnctura BV, Amsterdam, the Netherlands.ORCID 0000-0003-4525-0081
Pritom ShahCancer Research Horizons, Cambridge, United Kingdom.ORCID 0009-0001-7381-4609
Hilary SandigCancer Research Horizons, Cambridge, United Kingdom.ORCID 0009-0009-8258-0443
Hayley J SharpeThe Babraham Institute, Cambridge, United Kingdom.ORCID 0000-0002-4723-298X
Stuart FarrowCancer Research Horizons, Cambridge, United Kingdom.ORCID 0009-0007-1457-8371

Funding

Cancer Research UK Therapeutic Discovery Laboratories (CRUK-TDL)Wellcome Trust 109407
6 · The paper itself

Abstract

Autotaxin (ATX), encoded by ENPP2, is a clinical target in pancreatic ductal adenocarcinoma (PDAC). ATX catalyzes the production of lysophosphatidic acid (LPA), an important regulator within the tumor microenvironment (TME), yet the protumorigenic action of the ATX/LPA axis in PDAC remains unclear. In this study, by interrogating patient samples and cell line datasets, we show that the PDAC TME, rather than cancer cells, is responsible for the majority of ENPP2 expression and highlight a key role for cancer-associated fibroblast (CAF)-derived ATX in autocrine and paracrine protumorigenic signaling. Using the clinical-stage ATX inhibitor, IOA-289, we identified connective tissue growth factor (CTGF), also known as CCN2, as a downstream mediator of ATX signaling in the PDAC CAF-derived cell line, 0082T. Genetic ablation or pharmacologic inhibition of ATX in 0082T CAFs reduced CTGF secretion via modulation of LPA/LPA receptor signaling. Despite the loss of ATX function, extracellular levels of LPA were paradoxically increased, indicating a role for ATX beyond its enzymatic activity and suggesting a role for its LPA chaperone function in the LPA/LPA receptor signaling in CAFs. As CAFs are the main source for CTGF in the PDAC TME, these findings suggest a role for ATX in promoting a protumorigenic microenvironment via modulation of CAF secretion not only via its LPA-producing activity but also via its LPA chaperone function, providing a potential mechanism for the antitumor effects of ATX inhibition.

Indexed as

Cancer-Associated FibroblastsCarcinoma, Pancreatic DuctalConnective Tissue Growth FactorPancreatic NeoplasmsPhosphoric Diester HydrolasesAnimalsAutocrine CommunicationCell Line, TumorGene Expression Regulation, NeoplasticHumansLysophospholipase DLysophospholipidsMiceSignal TransductionTumor MicroenvironmentCCN2 protein, humanConnective Tissue Growth Factorlysophosphatidic acidLysophospholipase DLysophospholipidsPhosphoric Diester Hydrolases

Identifiers

PMID39570650
PMCPMC7618285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.